STOCK TITAN

Geron Corp. - GERN STOCK NEWS

Welcome to our dedicated news page for Geron (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Geron's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Geron's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
Geron Corp.

Nasdaq:GERN

GERN Rankings

GERN Stock Data

1.94B
474.96M
0.12%
67.9%
9.33%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Foster City

About GERN

we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.